None

Ranbaxy Laboratories, Dr Reddy's Laboratories, Nicholas Piramal and other pharmaceutical companies are betting on inlicensing or strategic marketing tie-ups to help grow local sales after India banned copying of patented drugs. According to analysts, Indian drug makers are forging alliances with overseas companies such as CD Pharma, Gnosis SpA, Crawford Healthcare and Syrio Pharma to sell drugs for chronic and acute cases.

Ranbaxy has signed a collaboration agreement with US-based Merck for drug discovery and clinical development in anti-infective drugs. Ranbaxy and Merck will work together to develop clinically validated anti-bacterial and anti-fungal drug candidates. Ranbaxy will carry out drug discovery and clinical development through Phase IIa clinical trials, with Merck conducting development and commercialization of drug candidates after that.

After consecutive litigation losses against Pfizer in its bid to grab a market share of the world's largest selling drug, Lipitor, Ranbaxy can now breathe easy. Last week, the Indian company got a shot in the arm, with the US Patent and Trademark Office (USPTO) issuing a a preliminary rejection of Pfizer's request for reissue of a patent for Lipitor. The verdict gives Ranbaxy hope to launch the cholesterol lowering drug Lipitor as early as March 2010.

Ranbaxy on Tuesday said that it has entered into a business alliance with Orchid Chemicals & Pharmaceuticals, involving multiple geographies and therapies for both finished dosage formulations and active pharmaceutical ingredients (raw materials). However, sources said the option of acquiring additional equity in Orchid, and announcing an open offer at a later stage, could not be ruled out.

Ranbaxy Laboratories (Ranbaxy) and Orchid Chemicals & Pharmaceuticals (Orchid) have announced that they have entered into a business alliance agreement involving multiple geographies and therapies for both finished dosage formulations and active pharmaceutical ingredients (APIs). Additionally, this agreement would establish a framework for enhanced future co-operation between the two companies.

Ranbaxy Laboratories Ltd has announced the launch of BONISTA- Teriparatide injection for the treatment of Osteoporosis, in collaboration with the Hyderabad-based Virchow Biotech Pvt Ltd. Ranbaxy is the first company to launch this bio-generic product in the world.

Country's largest drug maker, Ranbaxy, on Thursday announced the launch of 'BONISTA- Teriparatide' injection used in the treatment of Osteoporosis disease in collaboration with Hyderabad-based Virchow Biotech. BONISTA- Teriparatide injection is manufactured by recombinant human parathyroid hormone and Ranbaxy has become first company in the world to launch this bio-generic product, the company said in a filing to the BSE.

rbx11160, the much-touted first anti-malarial drug developed by drug major Ranbaxy's public-private partnership, will not be out until 2011. The drug may also not be available at a price the poor can afford.

ranbaxy in norway: The Norwegian Appeals Court ruled that Ranbaxy Laboratories Ltd's generic version of Lipitor did not infringe Pfizer Inc's patents. Ranbaxy says they will now be able to market their products in Norway. Pfizer markets its cholesterol-lowering drug Atorvastatin as Lipitor.

The Ranbaxy-Pfizer dispute involves three drugs:Lipitor, Caduet and Norvasc. The last named is a blood pressure drug. Pfizer's patent over it was annulled recently ending a lucrative monopoly:

Pages